Persistent Blood Stream Infection in Patients Supported With a Continuous-Flow Left Ventricular Assist Device Is Associated With an Increased Risk of Cerebrovascular Accidents

Abstract Background Common adverse events in patients supported with Continuous-flow left ventricular assist devices (CF-LVAD) include infections and cerebrovascular accidents (CVA). Some studies have suggested a possible association between blood stream infection (BSI) and CVA. Methods and Results...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiac failure 2015-02, Vol.21 (2), p.119-125
Hauptverfasser: Trachtenberg, Barry H., MD, Cordero-Reyes, Andrea M., MD, Aldeiri, Molham, MD, Alvarez, Paulino, MD, Bhimaraj, Arvind, MD, Ashrith, Guha, MD, Elias, Barbara, RN, Suarez, Erik E., MD, Bruckner, Brian, MD, Loebe, Matthias, MD, Harris, Richard L., MD, Zhang, J. Yi, MD, Torre-Amione, Guillermo, MD, PhD, Estep, Jerry D., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Common adverse events in patients supported with Continuous-flow left ventricular assist devices (CF-LVAD) include infections and cerebrovascular accidents (CVA). Some studies have suggested a possible association between blood stream infection (BSI) and CVA. Methods and Results Medical records of patients who received Heartmate II (HMII) CF-LVADs in 2008–2012 at a single center were reviewed. CVA was categorized as either hemorrhagic (HCVA) or ischemic (ICVA). BSI was divided into persistent (pBSI) and nonpersistent (non-pBSI). pBSI was defined as BSI with the same organism on repeated blood culture >72 hours from initial blood culture despite antibiotics. Univariate and multivariate analyses were performed to determine predictors. A total of 149 patients had HMII implanted; 76% were male, and the overall mean age was 55.4 ± 13 years. There were a total of 19 (13%) patients who had CVA (7 HCVA and 12 ICVA) at a median of 295 days (range 5–1,096 days) after implantation. There were a total of 28 (19%) patients with pBSI and 17 (11%) patients with non-pBSI. Patients with pBSI had a trend toward greater BMI (31 kg/m2 vs 27 kg/m2 ; P  = .09), and longer duration of support (1,019 d vs 371 d; P < .001) compared with those with non-pBSI. Persistent BSI was associated with an increased risk of mortality and with all-cause CVA on multivariate analysis (odds ratio [OR] 5.97; P  = .003) as well as persistent Pseudomonas aeruginosa infection (OR 4.54; P  = .048). Conclusions Persistent BSI is not uncommon in patients supported by CF-LVAD and is highly associated with all-cause CVA and increased all-cause mortality.
ISSN:1071-9164
1532-8414
DOI:10.1016/j.cardfail.2014.10.019